Timber Pharmaceuticals to Present at the 13th Annual LD Micro Main Event Conference
Timber Pharmaceuticals (TMBR) announced its participation in the 13th Annual LD Micro Main Event on December 15, 2020, at 10:40 AM EST. CEO John Koconis will present to a virtual audience, highlighting the company’s focus on treatments for rare dermatologic diseases. The event, known for its unique format of 10-minute presentations followed by Q&A sessions, aims to engage both executives and investors. This Main Event will be held on the Sequire Virtual Events platform, emphasizing innovative approaches to virtual conferences.
- None.
- None.
Presentation on Tuesday December 15th at 10:40am EST
LOS ANGELES, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announcedthat it will be presenting at the 13th annual LD Micro Main Event investor conference on Tuesday, December 15, 2020 at 10:40 AM EST / 7:40 AM PST. John Koconis, Chief Executive Officer of Timber Pharma, will be presenting to a live, virtual audience.
Register here: ve.mysequire.com/
The Main Event will feature a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.
"The time has finally come to do something different in the virtual conference world. Let’s see if we can pull off something that can be enjoyed by both executives and investors alike,” stated Chris Lahiji, Founder of LD, now a wholly owned subsidiary of SRAX, Inc.
The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform.
View Timber Pharmaceuticals profile here: http://www.ldmicro.com/profile/TMBR
Profiles powered by LD Micro
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and localized scleroderma. For more information, visit www.timberpharma.com.
About LD Micro/SEQUIRE
LD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visit ldmicro.com.
The upcoming Main Event will be highlighting a new format that will benefit both executives and the investors tuning in from all over the globe.
In September 2020, LD Micro. Inc. was acquired by SRAX, Inc., a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Form 10-Q filed on August 18, 2020 and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, contact:
Timber Pharmaceuticals, Inc.
John Koconis
Chief Executive Officer
Investor Relations:
Stephanie Prince
PCG Advisory
(646) 762-4518
Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
Source:Timber Pharmaceuticals via LD Micro
FAQ
When is Timber Pharmaceuticals presenting at the LD Micro Main Event?
Who is the CEO of Timber Pharmaceuticals?
What is the focus of Timber Pharmaceuticals?
What is the format of the LD Micro Main Event?
Where can I register for the LD Micro Main Event?
What is the stock symbol for Timber Pharmaceuticals?
